nasopharyngeal carcinoma
Conditions
Interventions
Intervention Group:Psychological intervention based on early warning system
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. No gender restriction, aged 18-70 years; 2. ECOG physical status score: 0-1 points; 3. Pathologically confirmed WHO type II and III nasopharyngeal carcinoma (according to the World Health Organization, WHO pathological score); 4. Stage III-IVa (according to the 8th edition of AJCC staging criteria), newly treated patients with nasopharyngeal carcinoma; 5. The treatment plan is induction chemotherapy followed by concurrent chemoradiotherapy: conventional fractionated IMRT ( PGTV: 22.20 Gy/Fx30-33F, 5F/W, total dose: >= 66.00 Gy/6.5W); the chemotherapy regimen is based on the platinum-based chemotherapy regimen selected by the investigator; 6. No serious heart disease, lung, liver, kidney and other important organ dysfunction; normal liver and kidney function: AST and ALT = 60 ml/min; adequate bone marrow function : peripheral blood leukocytes > 4.0x10^9/L, neutrophils > 2.0x10^9/L, hemoglobin > 90 g/L, platelets > 100x10^9/L; 7. The expected survival period is not less than 12 months; 8. The electronic questionnaire can be filled out independently; 9. The patients must be informed of the basic content of this study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Those who have previously suffered from other malignant tumors (except stage I non-melanoma skin cancer or carcinoma in situ of the cervix); 2. Those who have suffered from mental diseases in the past and have not been cured; 3. Those who received tumor-related treatment before enrollment; 4. Pregnant or breastfeeding women, women of childbearing age who are not contraceptive; 5. Accompanied by other serious comorbidities, which may bring greater risks or affect the compliance of the test. For example, unstable heart disease requiring treatment, severe cerebrovascular disease, ulcer disease, kidney disease, uncontrolled diabetes mellitus (fasting blood glucose > 1.5xULN), and mental illness, etc.; 6. Those without regular follow-up conditions; 7. Do not agree to sign the informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of anxiety/depression; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in anxiety/depression scores;Quality of Life;Efficacy evaluation;Incidence of acute toxicity; | — |
Countries
China
Contacts
Public ContactXing Lyu
Sun Yat-sen University Cancer Center
Outcome results
None listed